Weekly Roundup: June 22-26


ICYMI, this week’s edition features a video series on social media use in dermatology, the launch of our new podcast, as well as articles about FDA approvals for acne and cSCC, progress in epidermolysis bullosa, new rosacea management treatment, plus more.

In case you missed it, some of the articles we featured throughout the week take a look at the U.S. Food and Drug Administration (FDA) approval of tazarotene lotion 0.045% and adapalene 0.3% USP for acne vulgaris, as well as pembrolizumab for cutaneous squamous cell carcinoma (cSCC). We also highlighted progress in the pipeline for epidermolysis bullosa, JAK/SYK inhibitors for hand eczema, a video series on social media use in dermatology and the launch of the first episode of our podcast, The Cutaneous Connection.

Tazarotene topical for acne vulgaris launches in United States

Tazarotene lotion 0.045% (Arazlo, Ortho Dermatologics) is officially launched in the U.S. following approval by the U.S. Food and Drug Administration in late 2019 for the treatment of acne vulgaris in patients 9 years and older.

The Cutaneous Connection: Episode 1- Cannabinoid Use in Dermatology

In our first episode of The Cutaneous Connection, Adam Friedman, M.D., FAAD, discusses his recent presentation at the first virtual American Academy of Dermatology meeting about cannabinoids use in dermatology.

FDA approves Aleor’s adapalene gel for acne vulgaris

The U.S. Food and Drug Administration has approved the Abbreviated New Drug Application for topical retinoid adapalene gel USP, 0.3% from Alembic Pharmaceuticals and its joint venture Aleor Dermaceuticals for treatment of acne vulgaris.

Pembrolizumab approved by FDA for cSCC

The U.S. Food and Drug Administration has approved pembrolizumab for cutaneous squamous cell carcinoma whose disease has shown to not be curable by radiation or surgery.

Pipeline progress in epidermolysis bullosa

For the first time, there are trials looking at therapies that actually heal epidermolysis bullosa (EB) wounds, offering hope for patients suffering from the rare genetic disorder.

No evidence of increased cancer incidence in children using topical

A recent study shows no increased risk of incidence of malignancies in patients using topical tacrolimus. A black box warning on the therapy has made it challenging for physicians to prescribe, and researchers hope this evidence will lead to the FDA reconsidering that warning.

New treatments help improve rosacea managemen

Recent data sheds light on the pathogenesis of rosacea and outlines treatment options to better manage patients.

Dual JAK/SYK inhibitor a promising systemic treatment for chronic hand eczema

Gusacitinib, an investigational oral Janus kinase/spleen tyrosine kinase inhibitor, demonstrated statistical superiority compared with placebo for improving chronic hand eczema in a phase 2b study.

The Mainstream Patient: June 22

In this week's edition, we feature stories about dry brushing, the difference between psoriasis and eczema, comedone extractors, at-home microneedling, plus more.

Can you use social media to attract new patients?

In part one of our interview with Adam Friedman, M.D., FAAD, he discusses the data from a recent survey study that examines the influence of dermatologists' social media use on attracting new patients.

What do patients want to see from dermatologists on social media?

In part two of our conversation with Adam Friedman, M.D., FAAD, he offers insight on which patients look for a dermatologist on social media and what types of content produce the most engagement online.

How to interact with colleagues on social media

In part three of our video interview with Adam Friedman, M.D., FAAD, he discusses some of the benefits and pitfalls of colleague-to-colleague engagement on social media.

Dermatologists: Consider this before posting to social media

In the final installment of our conversation with Adam Friedman, M.D., FAAD, he details what dermatologists should keep in mind when posting to social media.

Biologics enter post-PASI era

With newer biologics consistently posting PASI improvements greater than 90%, dermatologists need to consider other factors when selecting a treatment. However, nuanced differences between the same drug class could be teased out, one expert says.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.